Helsinn and MEI begin dosing in Phase II combination trial to treat MDS

Swiss pharmaceutical group Helsinn and US-based oncology firm MEI Pharma have begun dosing patients in a Phase II clinical trial of pracinostat and azacitidine combination for the treatment of patients with myelodysplastic syndromes (MDS).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news